摘要背景药用植物以及绿色合成的银纳米颗粒(silver nanoparticles, AgNPs)
目前都已被证实是有效治疗糖尿病的药物来源. 当前这项研究聚焦于来源于山榄果水叶提取物的 …

Incretin‐based therapies, the most recent therapeutic options for type 2 diabetes mellitus
(T2DM) management, can modify various elements of the disease, including hypersecretion …

Abstract Sitagliptin (Januvia®, Xelevia™, Glactiv®, Tesavel®) is an orally administered,
potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first …

Cancer is a common comorbidity of diabetic patients; however, little is known about the
effects that antidiabetic drugs have on tumors. We discovered that common classes of drugs …

Background & aims Recently, the SAVOR TIMI-53 (Saxagliptin Assessment of Vascular
Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction …

Introduction In a previous pooled analysis of 19 double-blind clinical studies conducted by
Merck, which included data available as of July 2009 on 10,246 patients with type 2 …

Abstract Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a relatively new class of non-insulin
glucose-lowering agents, belonging to the incretin family, which are able to improve …

Objective To examine the association between dipeptidyl peptidase-4 inhibitors and
gallbladder or biliary diseases. Design Systematic review and pairwise and network meta …

Background To evaluate the risk of infections in the treatment of type 2 diabetes patients with
dipeptidyl‐peptidase 4 (DPP‐4) inhibitors. Methods A literature search was conducted …

Objective To compare the incidence of cardiovascular events and mortality in patients with
type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators. Methods A …